breast cancer

[Communications Biology] Scientists developed a pipeline for Multi-Sample long-read Transcriptome Assembly, which enabled construction of a transcriptome from long-read sequence data. Using the constructed transcriptome as a reference, they analyzed RNA extracted from 22 clinical breast cancer specimens.

[Nature Communications] Researchers described a human inflammatory breast cancer (IBC) cell line, A3250, that recapitulated key IBC features in a mouse xenograft model, including skin erythema, diffuse tumor growth, dermal lymphatic invasion, and extensive metastases.

[Molecular Cancer therapeutics] Scientists explored sulfated glycosaminoglycan (sGAG) levels as a predictor of TNBC response to platinum therapy. sGAG levels were quantified in three distinct TNBC tumor models including cell line-derived, patient-derived xenograft tumors, and isogenic models deficient in sGAG biosynthesis.

[Science Signaling] Researchers found that primary human adipocytes shed extracellular vesicles, specifically exosomes, that induced the expression of genes associated with epithelial-to-mesenchymal transition and cancer stem–like cell traits in cocultured breast cancer cell lines.

[Critical Reviews in Oncology Hematology] The authors conduct a meta-analysis, showing that the addition of programmed death-1/programmed death ligand-1 (PD-L1) blockade to chemotherapy improves progression-free survival in PD-L1 positive metastatic TNBC patients, also in the intention-to-treat population.

[Gilead Sciences, Inc.] Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Trodelvy® as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies.